Cytek Biosciences Inc. (CTKB)
NASDAQ: CTKBIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CTKB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $800.40M
- Forward P/E
- 87.43
- EPS (TTM)
- -$0.63
- Dividend yield
- None
- 52-week range
- 3.31 – 6.39
- Day range
- 5.99 – 6.39
- Volume / Avg
- 1.77M / 1.31M
- Beta
- —
- Shares outstanding
- 130.78M
52-week range
CTKB stock today
Shares of Cytek Biosciences (CTKB) finished lower on Nov 20 at $6.12, a drop of 3.16% or $0.20 per share, versus the S&P 500's 3.70% decline. At this level, CTKB sits near the top of its 52-week range of $3.31 to $6.39: 4.2% below the high, set on Nov 20, 2026 and 84.9% above the low. CTKB is up 21.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 4.1%.
Cytek Biosciences has posted a net loss over the last twelve months (EPS of -$0.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cytek Biosciences
Company profileCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Wenbin Jiang Ph.D.
- Headquarters
- Fremont, CA
- Employees
- 703
- IPO year
- 2021
- Website
- cytekbio.com
Financial highlights
Full financialsIn fiscal 2025, Cytek Biosciences generated $201.5 million in revenue, up 0.5% from fiscal 2024, its 5th consecutive year of revenue growth. Cytek Biosciences reported a net loss of $66.5 million, compared with a loss of $6.0 million a year earlier. Gross margin was 51.8% (down from 55.4%) and operating margin -20.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $201.49M | $200.45M | $193.01M | $2.96M | $2.18M |
| Growth | +0.52% | +3.85% | +6414.17% | +35.86% | +207.18% |
| Net income | $-66.54M | $-6.02M | $-12.15M | $2.48M | $3.03M |
| EPS (diluted) | $-0.52 | $-0.05 | $-0.09 | $0.02 | $0.00 |
Analyst forecast
ForecastConsensus (3 analysts)
buy
Avg. price target
$6.50+6.21%
- Strong buy 1
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.05 vs $-0.08
- Surprise
- +37.50%
CTKB news
All CTKB news- Cytek Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswire
- Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the YearGlobeNewswire
- Cytek Biosciences (CTKB) Q3 2026 Earnings Call TranscriptNasdaq
- Cytek Biosciences GAAP EPS of -$0.05 beats by $0.02, revenue of $53.2M beats by $0.25MSeeking Alpha
- Cytek Biosciences Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Cytek Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswire
- Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswire
Cytek Biosciences peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PACBPacific Biosciences of California Inc. | 1.63 | -7.39% | $508.95M | vs CTKB |
| NAUTNautilus Biotechnology Inc. | 2.12 | -2.30% | $270.03M | vs CTKB |
| LABStandard BioTools Inc. | 0.631 | +2.82% | $249.11M | vs CTKB |
| QTRXQuanterix Corporation | 1.96 | -3.45% | $93.06M | vs CTKB |
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs CTKB |
| HBIOHarvard Bioscience Inc. | 8.66 | -0.23% | $39.60M | vs CTKB |
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs CTKB |
| PRPOPrecipio Inc. | 17.35 | -6.17% | $31.11M | vs CTKB |
Indexes, lists and sector
Cytek Biosciences stock FAQ
What is Cytek Biosciences's stock price today?
CTKB last traded at $6.12 as of Nov 20, 4:00 PM EST, down 3.16% on the day. Prices are delayed at least 15 minutes.
Who is Cytek Biosciences's CEO?
Dr. Wenbin Jiang Ph.D. is the chief executive officer of Cytek Biosciences Inc., which has about 703 employees.
What is the CTKB 52-week high?
The 52-week high for CTKB is $6.39 and the 52-week low is $3.31. The stock is currently 4.2% below its high.